Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL

PHASE1RecruitingINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions
Non-Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

Azer-cel

Infusion of Allogeneic Anti-CD19 CAR T cells

DRUG

Fludarabine

Specified dose on specified days

DRUG

Cyclophosphamide

Specified dose on specified days

DRUG

IL-2

Specified dose on specified days

DRUG

Bendamustine

Specified dose on specified days

Trial Locations (22)

2050

RECRUITING

Royal Prince Alfred Hospital, Camperdown

2170

NOT_YET_RECRUITING

Liverpool Hospital, Liverpool

3065

RECRUITING

St Vincent's Hospital Melbourne, Fitzroy

5000

RECRUITING

Royal Adelaide Hospital, Adelaide

10021

ACTIVE_NOT_RECRUITING

Weill Cornell Medical College - NY Presbyterian Hospital, New York

10032

RECRUITING

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

21201

RECRUITING

University of Maryland, Baltimore

27708

COMPLETED

Duke University, Durham

30322

RECRUITING

Winship Cancer Institute Emory University, Atlanta

30342

RECRUITING

Northside Hospital Cancer Institute, Atlanta

33612

RECRUITING

H. Lee Moffitt Cancer Center, Tampa

43210

RECRUITING

Ohio State University, Columbus

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute (Wayne State University), Detroit

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

55455

RECRUITING

University of Minnesota, Minneapolis

75246

RECRUITING

Baylor University Medical Center, Dallas

77030

COMPLETED

MD Anderson, Houston

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

91010

RECRUITING

City of Hope, Duarte

02111

RECRUITING

Tufts Medical Center, Boston

02215

COMPLETED

Dana-Farber Cancer Institute, Boston

02903

RECRUITING

Lifespan Cancer Institute at Rhode Island Hospital, Providence

All Listed Sponsors
lead

Imugene Limited

INDUSTRY